Mutation Analysis Links Angioimmunoblastic T-Cell Lymphoma to Clonal Hematopoiesis
|
By LabMedica International staff writers Posted on 13 Oct 2021 |

Image: Bone marrow aspirate from a patient with peripheral T-cell lymphoma (Photo courtesy of Peter Maslak, MD)
Peripheral T-cell lymphoma (PTCL) is a heterogeneous group of lymphoid tumors and encompass peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS), angioimmunoblastic T-cell lymphoma (AITL), and several other entities of T-cell lymphoma.
A genetic analysis suggests that a rare blood cancer that affects immune T cells may be caused by exposure to smoking and aging-related mutations acquired during the early stage of production of new blood cells Mutations in blood cells likely caused by smoking and aging-related changes may lead to a rare type of blood cancer that affects immune cells.
Clinical Medical Laboratorians at Weill Cornell Medicine (New York, NY, USA) used next-generation genome sequencing to analyze 537 genes in 27 patients with AITL or PTCL for genetic changes that might lead to these T-cell tumors and to secondary cancers in some patients. All tissue samples (27 lymph node [LN] tissue specimens, 27 bone marrow [BM] aspirate/peripheral blood [PB] samples) were collected from 25 AITL or two PTCL NOS patients who were diagnosed or confirmed from June 2010 to December 2019.
The tumor burden estimate was also based on more objective and sensitive immunophenotypic findings by flow cytometry). A 537-gene targeted sequencing panel, based on hybridization capture method for sequencing library construction and selection, was designed to investigate the genomic profile of the primary tumors and the BM/PB tissues. The NGS libraries were constructed using the KAPA Hyperplus Kit (Roche, Basel, Switzerland), and hybrid selection was performed with the probes from the customized Twist Library Prep Kit (Twist Biosciences, San Francisco, CA, USA). Multiplexed libraries were sequenced using 150 bp paired end HiSeq 4000 sequencers (Illumina, San Diego, CA, USA). Targeted enrichment of 45 genes recurrently mutated in myeloid malignancies was performed using the Thunderstorm system with a customized primer panel.
The scientists reported that in about 70% of the patients, there were mutations in precursor cells, most likely stem cells, in the bone marrow that can lead to the production of growing numbers of blood cells with these mutations, as well as early development of the T-cell tumors. These mutations in the precursor cells have been thought to be related to aging. In addition, the team found that the mutations associated with the progression of these tumors might be linked to smoking or exposure to second-hand smoke. They also found that patients with a higher mutation burden of one of the genes associated with the early development of these tumors were at higher risk of developing additional types of tumors.
Wayne Tam, MD, PhD, a Professor of Pathology and Laboratory Medicine and senior author of the study, said, “Our results provide new information on how exposure to smoking may cooperate with early mutations in blood precursor cells to lead to the development of certain T-cell cancers. The findings suggest a potential new way to identify patients with AITL or PTCL who are most at risk of developing secondary tumors, and may also help scientists and clinicians improve how these cancers are prevented, diagnosed and treated.”
The authors concluded that they provided genetic evidence that AITL/PTCL-NOS, clonal hematopoiesis (CH), and concomitant hematologic neoplasms (CHN) can frequently arise from common mutated hematopoietic precursor clones. The study also suggests smoking exposure as a potential risk factor for AITL/PTCL-NOS progression. The study was published on September 28, 2021 in the journal eLife.
Related Links:
Weill Cornell Medicine
Roche
Twist Biosciences
Illumina
A genetic analysis suggests that a rare blood cancer that affects immune T cells may be caused by exposure to smoking and aging-related mutations acquired during the early stage of production of new blood cells Mutations in blood cells likely caused by smoking and aging-related changes may lead to a rare type of blood cancer that affects immune cells.
Clinical Medical Laboratorians at Weill Cornell Medicine (New York, NY, USA) used next-generation genome sequencing to analyze 537 genes in 27 patients with AITL or PTCL for genetic changes that might lead to these T-cell tumors and to secondary cancers in some patients. All tissue samples (27 lymph node [LN] tissue specimens, 27 bone marrow [BM] aspirate/peripheral blood [PB] samples) were collected from 25 AITL or two PTCL NOS patients who were diagnosed or confirmed from June 2010 to December 2019.
The tumor burden estimate was also based on more objective and sensitive immunophenotypic findings by flow cytometry). A 537-gene targeted sequencing panel, based on hybridization capture method for sequencing library construction and selection, was designed to investigate the genomic profile of the primary tumors and the BM/PB tissues. The NGS libraries were constructed using the KAPA Hyperplus Kit (Roche, Basel, Switzerland), and hybrid selection was performed with the probes from the customized Twist Library Prep Kit (Twist Biosciences, San Francisco, CA, USA). Multiplexed libraries were sequenced using 150 bp paired end HiSeq 4000 sequencers (Illumina, San Diego, CA, USA). Targeted enrichment of 45 genes recurrently mutated in myeloid malignancies was performed using the Thunderstorm system with a customized primer panel.
The scientists reported that in about 70% of the patients, there were mutations in precursor cells, most likely stem cells, in the bone marrow that can lead to the production of growing numbers of blood cells with these mutations, as well as early development of the T-cell tumors. These mutations in the precursor cells have been thought to be related to aging. In addition, the team found that the mutations associated with the progression of these tumors might be linked to smoking or exposure to second-hand smoke. They also found that patients with a higher mutation burden of one of the genes associated with the early development of these tumors were at higher risk of developing additional types of tumors.
Wayne Tam, MD, PhD, a Professor of Pathology and Laboratory Medicine and senior author of the study, said, “Our results provide new information on how exposure to smoking may cooperate with early mutations in blood precursor cells to lead to the development of certain T-cell cancers. The findings suggest a potential new way to identify patients with AITL or PTCL who are most at risk of developing secondary tumors, and may also help scientists and clinicians improve how these cancers are prevented, diagnosed and treated.”
The authors concluded that they provided genetic evidence that AITL/PTCL-NOS, clonal hematopoiesis (CH), and concomitant hematologic neoplasms (CHN) can frequently arise from common mutated hematopoietic precursor clones. The study also suggests smoking exposure as a potential risk factor for AITL/PTCL-NOS progression. The study was published on September 28, 2021 in the journal eLife.
Related Links:
Weill Cornell Medicine
Roche
Twist Biosciences
Illumina
Latest Molecular Diagnostics News
- Blood Test Predicts Immunotherapy Response in Head and Neck Cancer
- New PCR Assay Supports Bundibugyo Ebola Outbreak Surveillance
- Blood-Based RNA Test May Predict Chemotherapy Sensitivity in Lung Cancer
- Plasma Protein Signature Predicts Lung Cancer Risk Up to Five Years Ahead
- Circulating Tumor DNA Testing Guides Chemotherapy, Reduces Relapse in Colon Cancer
- Researchers Uncover Distinct Chromosome Signature in Aggresive ALT Cancers
- Simple Cytogenetic Method Could Improve Classification of ALL Subtypes
- Blood-Based Assay Enables Noninvasive Monitoring of Sarcoma Immunotherapy Response
- Genomic Test Guides Chemotherapy Decisions in Early-Stage Breast Cancer
- Tumor Mutation Marker Helps Refine Lung Cancer Prognosis and Guide Therapy Selection
- Multi-Cancer Test Boosts Detection When Added to Standard Screening
- Blood-Based MRD Monitoring Supports Relapse Prevention in Leukemia
- Genomic Test Predicts Chemotherapy Benefit in Metastatic Prostate Cancer
- Blood Protein Markers Flag Multiple Sclerosis Risk Years Before Diagnosis
- Digital PCR Assays Support Surveillance of Bundibugyo Ebolavirus Outbreak
- Updated Guidance Prioritizes Stool-Based Colorectal Cancer Screening Tests
Channels
Clinical Chemistry
view channel
Urinary Biomarker Assay Predicts Kidney Disease Progression Beyond Standard Measures
Many patients with type 2 diabetes and chronic kidney disease continue to experience progressive renal decline, yet conventional markers such as albuminuria and estimated glomerular filtration rate (eGFR)... Read more
Saliva-Based Test Detects Biochemical Signs of Sleep Loss
Acute sleep loss impairs cognition and motor skills, raising safety risks that resemble alcohol intoxication. Clinicians currently lack an objective biochemical test to determine when someone is dangerously... Read more
Simple Dual-Tau Blood Test Detects and Stages Alzheimer’s Disease
Alzheimer’s disease is typically confirmed and staged with positron emission tomography scans and cerebrospinal fluid testing, procedures that are costly and invasive. Broader access to minimally invasive... Read more
Alzheimer’s Blood Biomarkers Linked to Early Cognitive Differences Before Dementia
Blood-based screening for Alzheimer’s disease offers a noninvasive, lower-cost alternative to brain imaging or spinal fluid testing, yet its ability to flag the earliest cognitive changes has been unclear.... Read moreMolecular Diagnostics
view channel
Blood-Based RNA Test May Predict Chemotherapy Sensitivity in Lung Cancer
Lung cancer care increasingly relies on biomarker-guided patient stratification, but tissue biopsy can be impractical and treatment selection remains difficult for many patients. Blood-based assays that... Read more
Blood Test Predicts Immunotherapy Response in Head and Neck Cancer
Head and neck squamous cell carcinoma affects hundreds of thousands of people worldwide each year, yet response rates to immunotherapy remain low. Clinicians lack reliable, minimally invasive tools to... Read moreImmunology
view channelAptamer-Based Biosensor Enables Mutation-Resilient SARS-CoV-2 Detection
Rapid evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can undermine existing molecular diagnostics, especially when assays target small viral components. Double-antibody sandwich... Read more
Study Points to Autoimmune Pathway Behind Long COVID Symptoms
Long COVID leaves many SARS-CoV-2 survivors with persistent fatigue, cognitive issues, palpitations, and musculoskeletal pain for months or years. Estimates cited in new research suggest 4%–20% of infected... Read more
Metabolic Biomarker Distinguishes Latent from Active Tuberculosis and Tracks Treatment Response
Tuberculosis (TB) remains the world’s leading infectious killer, with 10.8 million cases and 1.25 million deaths recorded globally in 2023. Yet many infected individuals never develop active disease, underscoring... Read moreMicrobiology
view channel
New Culture Medium Speeds C. difficile Resistance Detection and Reduces Costs
Clostridioides difficile infections remain a persistent threat in hospitals and communities, affecting about 500,000 people in the United States each year. Severe cases can be fatal within 30 days of diagnosis,... Read more
Automated Blood Culture System Speeds Detection of Bloodstream Infections
Bloodstream infections and sepsis require rapid laboratory detection to guide targeted antimicrobial therapy and reduce mortality. Conventional blood culture workflows can delay actionable results by critical... Read morePathology
view channel
AI Pathology Tool Predicts Meningioma Recurrence from Routine Slides
Meningiomas are the most common primary brain tumors in adults, yet their course ranges from indolent to highly recurrent disease. Estimating an individual patient’s recurrence risk often requires advanced... Read more
3D Spatial Multi-Omics Maps Intra-Tumor Diversity in Colorectal Cancer
Colorectal cancer remains a leading cause of cancer death, and clinical decision-making is complicated by marked intra-tumor heterogeneity. Conventional bulk sequencing averages molecular signals across... Read moreTechnology
view channel
AI Platform Links Biomarker Results to Cancer Clinical Trials and Guidelines
Oncology teams must manage growing volumes of genomic data, rapidly evolving clinical trial options, and frequently updated care guidelines, all within tight clinic schedules. Translating complex tumor... Read more
Agentic AI Platform Supports Genomic Decision-Making in Oncology
Oncology care teams increasingly face the challenge of managing complex molecular diagnostics, evolving treatment options, and extensive electronic health record documentation. Translating multimodal data... Read moreIndustry
view channel
Genetic Testing Program Expands Detection of Alpha-1 Antitrypsin Deficiency
Alpha-1 Antitrypsin Deficiency (AATD) is a progressive genetic condition, the leading known genetic risk factor for chronic obstructive pulmonary disease (COPD), and a cause of liver disease in both children... Read more








